POSSIBILITIES OF SYSTEMIC RADIONUCLIDE THERAPY IN PALLIATIVE TREATMENT OF P ATIENTS WITH METASTATIC BONES DISEASE
https://doi.org/10.17709/2409-2231-2014-1-1-57-61
Abstract
The pain syndrome accompanying metastatic damage of bones, significantly reduces quality of patients life. In recent decades, medical practice implemented methods systemic radionuclide therapy of bone metastases using different radionuclides, which allows to stop both the pain and the progression of the disease. Results of their application give the grounds to consider the perspective development in nuclear medicine of the direction on treatment bone metastatic defeats by means of systemic radionuclide therapy.
About the Authors
A. D. Kaprin
Hertsen FMRC MH RF (Obninsk, Russian Federation) 4, st. Korolev, 249036, Russian Federation, Kaluga region, Obninsk
Russian Federation
Russian Federation
RAS Corr. Mem., MD, Prof.; Corresponding Member of the Russian Academy of Education;Honored Physician of the Russian Federation; General Director Hertsen Federal Medical Research Centr of the Ministry of Health of the Russian Federation; Director Moscow Oncology Institute of the Hertsen FMRC MH RF, Head, Department of Urology with Course of Urological Oncology, Faculty for Postgraduate
Training, Peoples’ Friendship University of Russia; Principal Urologist, Academy of Sciences of the Russian Federation
ORCID 0000-0001-8784-8415
A. A. Kostin
Hertsen FMRC MH RF (Obninsk, Russian Federation) 4, st. Korolev, 249036, Russian Federation, Kaluga region, Obninsk
Russian Federation
Russian Federation
MD., Prof., First Deputy General Director Hertsen Federal Medical Research Centr of the Ministry of Health of the Russian Federation ORCID 0000-0002-0792-6012
A. V. Leontyev
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Competing Interests:
Russian Federation
Competing Interests:
PhD, head of nuclear medicine Moscow Oncology Institute of the Hertsen FMRC MH RF 3, 2 Botkinskiy proezd, 125284, Russian Federation, Moscow Теl: +7 (495) 945-87-18,
T. N. Lazutina
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
MD, radiologist department of nuclear medicine Moscow Oncology Institute of the Hertsen FMRC MH RF
I. V. Pylova
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
MD, radiologist separating radionuclide diagnostics Moscow Oncology Institute of the Hertsen FMRC MH RF
L. V. Dushakova
Moscow Oncology Institute of the Hertsen FMRC MH RF (Moscow, Russian Federation) 3, 2 B otkinskiy proezd, 125284, Russian Federation, Moscow
Russian Federation
Russian Federation
separation, document the diagnosis and treatment Moscow Oncology Institute of the Hertsen FMRC MH RF, Head of the Laboratory of the Department of Urology and Surgical Nephrology oncourology with the course of the Medical Faculty of the Medical Institute of People’s Friendship University.
References
1. Menshikova E.S. Palliativnoe lechenie bol’nyh s kostnymi metastazami zlokachestvennyh opuholej s ispol’zovaniem stroncija-89 hlorida // Avtoref. k.m.n. - 2008 g.
2. Riccabona G. Nuclear medicine in diagnosis and therapy of bone and joint diseases [Journal] // Nucl. Med. Rev. - 1999. - Vol. 2. - pp. 42–52.
3. Kraeber-Bodere F., Campion L., Rousseau C. et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement [Journal] // Eur. J. Nucl. Med. - 2000. - Vol. 27. - pp. 1487–1493.
4. Maxfield J.J.R., Maxfield J.G.S., Maxfield W.S. The use of radioactive phosphorous and testosterone on metastatic bone lesions from breast and prostate [Journal] // Sth. Med. J. - 1958.- Vol. 35. - p. 320.
5. Berna L., Carrio I., Alonso C. Bone pain palliation with strontium -89 in breast cancer patiens with bone metastases and refractory bone pain [Journal] // Eur. J. Nucl. Med. - 1995. - Vol. 22. - pp. 1101-1104.
6. Vasil’ev A.Ju., Shherbakov S.D., Krasnova Je.V. i dr. Opyt lechenija kostnyh metastazov hloridom stroncija-89 [Zhurnal] // Med. radiologija i radiac. bezopasnost’. - 2003 g. - T. 48. - str. 66-69.
7. Menshikova E.S., Vazhenin A.V., Sharabura T.M., Vaganov N.V. Ocenka jeffektivnosti stroncija-89 hlorida v sochetanii s distancionnoj luchevoj terapiej kostnyh metastazov raka predstatel’noj i molochnoj zhelez [Zhurnal] // Sibirskij onkologicheskij zhurnal. - 2008 g. - T. 3. - str. 34-37.
8. Krylov V.V. Radionuklidnaja terapija samariem oksabiforom, 153 Sm pri metastaticheskom porazhenii kostej // Avtoreferat. - Obninsk : [b.n.], 2007 g.
9. Palmedo H., Bender H., Schomburg A. Pain therapy with rhenium-186 HEDP in multiple bone metastases [Journal] // Nuklearmedizin. - 1996. - Vol. 35. - pp. 63-67.
10. Guerra U.P., Englaro E., Cattruzzi E. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer [Journal] // Tumori. - 1997. - Vol. 83. - pp. 560-62.
11. Li S., Liu J., Zhang H. et al. Rhenium-188 HEDP to treat painful bone metastases [Journal] // Clin Nucl Med. - 2001. - Vol. 26. - pp. 919-22.
12. Palmedo H., Manka Waluch A., Albers P. et al. Repeated bone_targeted therapy for hormone_refractory prostate carcinoma: Randomized phase II trial with the new, high_energy radiopharmaceutical rhenium_188 hydroxyethylidenediphosphonate [Journal] // J. Clin. Oncol. - 2003. - Vol. 21. - pp. 2869-2875.
13. Voloznev L.V., Klement’eva O.E., Korsunskij V.N. i dr. Jeksperimental’naja ocenka funkcional’noj prigodnosti radiofarmacevticheskogo preparata 188re-zoledronovaja kislota [Zhurnal] // Molekuljarnaja medicina. - 2013 g. - T. 2.- str. 42-45.
14. Kluetz P.G., Pierce W., Maher V.E. et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary [Journal] // Clin Cancer Res. - 2014. - Vol. 20. - pp. doi: 10.1158/1078-0432.CCR-13-2665. Epub 2013 Nov 4.
Review
For citations:
Kaprin A.D., Kostin A.A., Leontyev A.V., Lazutina T.N., Pylova I.V., Dushakova L.V. POSSIBILITIES OF SYSTEMIC RADIONUCLIDE THERAPY IN PALLIATIVE TREATMENT OF P ATIENTS WITH METASTATIC BONES DISEASE. Research and Practical Medicine Journal. 2014;1(1):57-61. (In Russ.) https://doi.org/10.17709/2409-2231-2014-1-1-57-61
Views:
1555
Email this article 